Targets › MYC
6 programs from 6 companies in 8 trials: 4 Phase 1, 3 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.
Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. (UniProt, P01106)
Open in Phaseline: the race on MYC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | ABVD regimen Combination of doxorubicin, bleomycin, vinblastine, and dacarbazine - multi-modal chemothe | Tubulin, TOP2A, MYC | Phase 3 | Lymphoma | – |
| Institute of Hematology & Blood Diseases Hospital, China | DVRd Daratumumab (CD38 monoclonal antibody), Velcade (proteasome inhibitor), and dexamethasone | PSMD1, TP53, MYC | Phase 2 | Multiple Myeloma | Dec 2026 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | ZEN-3694 MYC inhibitor | MYC | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Aug 2031 |
| IDP Discovery Pharma | IDP-121 cMyc protein antagonist | MYC | Phase 1 | Multiple Myeloma (MM); Small Cell Lung Cancer ( SCLC ) | Jul 2028 |
| National Institute of Neurological Disorders and Stroke (NINDS) | LMP744 Indenoisoquinolone C-MYC/TOPOISOMERASE 1 inhibitor | MYC, TOP1 | Phase 1 | Recurrent Glioblastoma | Dec 2030 |
| Peptomyc | OMO-103 Myc inhibitor | MYC | Phase 1 | Metastatic Pancreatic Cancer; Osteosarcoma | – |
Recurrent Glioblastoma (1) Lymphoma (1) Multiple Myeloma (1) Metastatic Pancreatic Cancer (1) Osteosarcoma (1) Metastatic Castration-resistant Prostate Cancer (1) Multiple Myeloma (MM) (1) Small Cell Lung Cancer ( SCLC ) (1)
small molecule (5), mixed (1)
National Institute of Neurological Disorders and Stroke (NINDS) (1) European Organisation for Research and Treatment of Cancer - EORTC (1) Institute of Hematology & Blood Diseases Hospital, China (1) Peptomyc (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) IDP Discovery Pharma (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.